Passion and purpose to transform standards of care

Dr. Williamson is currently a CNS Drug Development Consultant and founder of Destiny Biopharm Consulting. Most recently, he served as Chief Medical Officer of QurAlis Corporation. Prior to QurAlis, he was Executive Vice President, Head of Research and Development at Acadia Pharmaceuticals Inc., where he led the company’s research and development strategy across its neuroscience pipeline and served on its Executive Management Committee. Earlier in his career, Dr. Williamson served as Chief Medical Officer of Avadel Pharmaceuticals and held senior leadership positions at H. Lundbeck A/S, including Senior Vice President, Head of U.S. Research and Development, and Deputy Global Chief Medical Officer. He also served as Vice President, Global Head of Therapeutic Area Leadership at Parexel International. During his tenure at Eli Lilly and Company, Dr. Williamson contributed to the development and regulatory approval of several neuropsychiatric therapies, including Symbyax for treatment-resistant depression and bipolar depression, Zyprexa for bipolar maintenance, and supported the commercial development of Cymbalta. Dr. Williamson previously served on the Board of Bright Minds Biosciences (Nasdaq: DRUG), and was a member of its Compensation, Audit, Nomination and Corporate Governance Committees. He holds a medical degree from the University of Edinburgh.